Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Cardiotoxicity 3Breast Neoplasms 3Lymphoma, B-Cell 2Leukemia 2Burkitt Lymphoma 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Solid Tumors 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Echocardiography × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡